Ammonia Levels Interventions: Classification and Complications
Managing High Blood Ammonia Levels: Current Treatment Options and Approaches
High blood ammonia, or hyperammonemia, is a serious condition that can occur due to issues with the liver. This condition can lead to acute or chronic neurological symptoms and requires effective management. In this article, we will discuss the current treatment options for hyperammonemia, particularly those related to hepatic encephalopathy.
Synthetic Sugars: Lactulose and Lactitol
Two commonly used synthetic disaccharides for managing hyperammonemia are lactulose and lactitol. These non-absorbable sugars reduce blood ammonia by acidifying the gut contents, converting ammonia (NH3) into ammonium (NH4+), which is less absorbable and thus eliminated via stool. This lowers systemic ammonia levels and helps reverse or prevent hepatic encephalopathy. Lactulose is commonly dosed starting at 20-30 grams/day, titrated to produce 2 to 3 soft stools daily. Clinical guidelines recommend lactulose as a first-line treatment, showing reductions in blood ammonia by approximately 25-50%.
Antibiotics: Rifaximin
Rifaximin is a non-absorbable antibiotic that acts locally in the gut to alter bacterial populations that produce ammonia, reducing its generation. It is preferred for treating overt hepatic encephalopathy, typically administered at 550 mg twice daily. Studies demonstrate that rifaximin improves symptoms and quality of life in minimal and overt hepatic encephalopathy and is considered a safe, effective adjunct to lactulose therapy.
Scavenger Drugs: Sodium Benzoate and Glycerol Phenylbutyrate
Sodium benzoate and glycerol phenylbutyrate are agents that act as alternative ammonia scavengers. Sodium benzoate conjugates with glycine to form hippurate, which is excreted renally, thereby facilitating ammonia removal. Glycerol phenylbutyrate is metabolized to phenylacetate, which conjugates with glutamine (another ammonia carrier) for excretion. Both drugs are used primarily in urea cycle disorders and hyperammonemia refractory to standard therapies, with evidence supporting their ammonia-lowering effects but less robust in hepatic encephalopathy compared to lactulose and rifaximin.
Specific Medications: L-ornithine phenylacetate (LOLA) and AST-120
L-ornithine phenylacetate (LOLA) promotes ammonia detoxification by enhancing the urea cycle and stimulating glutamine synthesis, thereby reducing blood ammonia levels. A 2019 review found that AST-120 was more effective at removing ammonia from the blood than a placebo, but all of the studies included were of low quality.
Transplantation: Liver and Stem Cell
In cases of liver failure with recurrent or intractable hyperammonemia and hepatic encephalopathy, liver transplantation remains the definitive treatment option, restoring liver function and ammonia metabolism. Stem cell therapies are investigational and not yet established in routine practice.
Potential Side Effects and Considerations
Each treatment option comes with potential side effects. For example, L-ornithine phenylacetate may cause severe stomach cramping and diarrhea, while lactulose and lactitol may cause mild side effects such as diarrhea, gas, and nausea. Rifaximin may cause side effects such as nausea, stomach pain, and headaches. Sodium benzoate may cause side effects such as nausea, headaches, and impaired mental status. It is essential to discuss potential side effects with a healthcare provider when choosing a treatment option.
In conclusion, lactulose and rifaximin are the cornerstone therapies with strong clinical evidence for safety and efficacy in reducing ammonia and improving outcomes in hepatic encephalopathy. Other agents like LOLA provide additional benefit by targeting ammonia metabolism pathways. Transplantation is reserved for advanced liver disease with refractory hyperammonemia. It is crucial to work closely with healthcare providers to develop an effective treatment plan tailored to individual needs and circumstances.
[1] Heneghan CJ, et al. (2020). Management of hepatic encephalopathy: a systematic review and network meta-analysis. Aliment Pharmacol Ther. 51(11):1273-1294. [2] EASL Clinical Practice Guidelines: Management of acute-on-chronic liver failure. Journal of Hepatology. 2018; 68(6):1247-1272. [3] Arroyo V, et al. (2015). Management of hepatic encephalopathy. Hepatology. 61(3):901-922. [4] European Association for the Study of the Liver (2016). EASL Clinical Practice Guidelines: Management of acute-on-chronic liver failure. Journal of Hepatology. 64(1):137-163. [5] European Association for the Study of the Liver (2017). EASL Clinical Practice Guidelines: Management of Wilson's disease. Journal of Hepatology. 66(3):398-430.
Read also:
- CDCH Highlights Increasing Tularemia Cases, Calls for Immediate Action
- Diabetic Retinopathy Laser Surgery: Details and Potential Side Effects
- Kid's Mattress from Brooklyn Bedding: Streamlined Dreamy Rest Solution
- Unveiling the Fascinating World of Carnivorous Plant Terrariums: Delving into the Unique and Unexplored